



Preclinical PET/CT imaging of colon-infiltrating CD4⁺ T cells with ⁸⁹Zr-df-IAB46 in a dextran sodium sulfate-induced mouse model of acute and chronic ulcerative colitis

Julia Baguña Torres¹, Álvaro Valverde Moya¹, Itziar Busquets Sáez¹, Noemí Gómez Lado^{2,3}, Xurxo García Otero^{2,3}, Lara García Varela^{2,3}, Johanna Troya-Balseca¹, Carolina Aparicio-Gómez¹, Jana Vidal Otero¹, Santiago Aguadé Bruix¹, Pablo Aguiar Fernández^{2,3} and José Raúl Herance Camacho¹

¹Vall d'Hebron Research Institute, CIBBIM-Nanomedicine, Universidad Autónoma de Barcelona, CIBERbbn, Barcelona, Spain. ²Molecular Imaging Biomarkers Group, CIMUS Research Institute, Faculty of Medicine, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain. ³Molecular Imaging Biomarkers Group and Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n Santiago de Compostela, Spain.

Background

Ulcerative colitis (UC) is a type of inflammatory bowel disease characterized by chronic inflammation of the large intestine, mainly mediated by CD4⁺ T lymphocytes (Geremia A. *et al.*, Autoimmun Rev. 2014;13:3–10). A probe for non-invasive PET imaging of CD4⁺ Th-cell dynamics could be used to identify the cell subsets responsible for colonic inflammation, as well as to assess response to therapy for clinical diagnostic and drug development applications. Here, the utility of anti-CD4 minibody (IAB46) as an immuno-PET probe to measure CD4⁺ T-cell levels *in vivo* was evaluated in a dextran sodium sulfate (DSS)-induced mouse model of UC.

Results







(American Gastroenterological Association, 2022)

Severe active chronic colitis with multifocal colonic surface ulceration as shown by H&E staining (PathologyOutlines.com, Inc., 2023).

Methods

DSS-induced mouse model of UC

• C57BL/6J, F, 8-10 wo

 1 or 3 x 5-day cycles of 2.5% DSS in drinking water + 7-day unsupplemented water



Radiosynthesis of ⁸⁹Zr-df-IAB46

- Anti-mouse CD4 minibody (ImaginAb, Inc.) conjugated to deferoxamine and radiolabeled with ⁸⁹Zr.
- RCP > 95%, SA 0.3 MBq/µg





Conclusions

- ⁸⁹Zr-DFO-IAB46 accumulated mainly in secondary lymphoid organs and tissues, such as spleen and lymph nodes, and was primarily excreted into the bile.
- Splenic tracer uptake was found to be significantly higher in wildtype controls at 24h

In vivo PET/CT imaging

- 5 µg of ⁸⁹Zr-df-IAB46 (~1.5 MBq) injected intravenously to all mice.
- Negative controls: wildtype mice and colitic mice injected with 15-fold unlabeled df-IAB46 2 hours before tracer injection.
- Iohexol was injected intrarectally for contrast-enhanced CT imaging of the large intestine.
- PET images were quantified via VOI analysis using 3D fixed-volumes and semiautomatic iso-contouring methods.
- Excised colon tissue was examined by H&E and immunofluorescence staining.



0

Colon segmentation

on contrast-enhanced

CT images

post-injection compared to mice with chronic colitis.

- Lymph node CD4 signal was significantly higher in DSS-treated mice at the chronic phase compared to wildtype controls but was not effectively blocked.
- PET signal was higher in the distal colon in both mice with acute and chronic colitis compared to wildtype littermates.

Acknowledgements

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This research is also supported by Vall d'Hebron University Hospital, AGAUR, ISCIII, VHIR & "Ia Caixa" Foundation (ID 100010434, fellowship code LCF/BQ/ PR22/11920002). The authors are particularly grateful to our collaborators at ImaginAb Inc., who provided the df-IAB46 conjugate that was used in this study.